EMA Approves WINREVAIR (Sotatercept) for Treatment of PAH
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial Hypertension (PAH).
Report from the International PHA conference
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients, and advocates from around the world, all united by a shared commitment to advancing the understanding and treatment of pulmonary
TORREY results in Lancet
The pharmaceutical company Gossamer Bio, celebrates a significant achievement with the publication of its TORREY Phase 2 study results in the esteemed Lancet Respiratory Medicine journal.
Report from IMPAHCT 2024
Approximately 150 pulmonary hypertension (PH) specialists convened in Barcelona in April 2024 for Ferrer’s 6th edition of the IMPAHCT meeting. Notably, Hall Skaara represented PHA Europe for the second time at the conference, serving as the sole patient advocate present.
FDA recently approved Opsynvi
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Sotatercept approved by FDA
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the treatment of adults with pulmonary arterial hypertension (PAH).
Report from SAPH2024
The Saudi Association for Pulmonary Hypertension (SAPH) hosted its 17th annual conference in Riyadh, Saudi Arabia, from February 15 to 17, 2024. The conference featured an impressive scientific program with sessions led by numerous leading PH specialists from around the world.
Report from the IMPACHT conference in Barcelona June 30th – July 1st
Ferrer annually hosts a conference known as IMPACHT (International Meeting on Pulmonary Hypertension Clinical Treatment) that caters to pulmonologists and cardiologists.
APHEC 2022
Due to the COVID pandemic, the annual PH European conference (APHEC) had to be run virtually. This has worked very well as we utilised an excellent online platform where we rebuild our conference hotel in Barcelona.
Invitation to PHA Europe’s virtual annual conference (APHEC) – 2021
Our conference hall is now available. Here you will be able to see presentations by leading PH specialist from last year’s conference and the presentations for this year’s conference will be available during the month of February. A wide range of topics are covered from
3rd Baltic Pulmonary Hypertension and Circulation Conference
Estonia, Tallinn – 01.10.2021 09:30 – 01.10.2021 20:00 [hybrid event] Years of dedication and collaboration within the pulmonary hypertension (PH) community have vastly increased our knowledge of this progressive disease. This has led to the intelligent use of targeted therapies and evidence-based management strategies, which
Invitation to PHA Europe’s virtual annual conference (APHEC)
The conference hall will be available from February 28th. Here you will be able to see presentations by leading PH specialist talking about the future of PAH medication, PH and Covid-19, transplant issues, etc. In addition, you will see presentations about subjects like yoga, breathing
Scientific conferences 2014
In the course of 2014 PHA Europe representatives were present at the two largest events in the fields of cardiology and respiratory medicine. The 2014 annual congress of the European Society of Cardiology was held in Barcelona (Spain) from August 30 to September 3 and
Drug Information
Three new drugs for pulmonary hypertension have been approved by the US and/or EU regulatory authorities in the course of the last year: